Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy

Journal of Gastroenterology

Volumn 51, Issue 11, 2016, Pages 1081-1089

  Hayashi, Kazuhiko ^a   Ishigami, Masatoshi ^a   Ishizu, Yoji ^a   Kuzuya, Teiji ^a   Honda, Takashi ^a   Tachi, Yoshihiko ^b   Ishikawa, Tetsuya ^a   Katano, Yoshiaki ^c   Yoshioka, Kentaro ^d   Toyoda, Hidenori ^e   Kumada, Takashi ^e   Goto, Hidemi ^a   Hirooka, Yoshiki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOMAKI CITY HOSPITAL   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Genotype; Hepatitis B virus; Phylogenetic analysis; Reactivation

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FULMINANT HEPATIC FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; MALE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REACTIVATION; AGE; AMINO ACID SEQUENCE; BLOOD; DRUG EFFECTS; GENETICS; GENOTYPE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PHYLOGENY; PHYSIOLOGY; RISK FACTOR; SEQUENCE ALIGNMENT; SEX DIFFERENCE; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHYLOGENY; RISK FACTORS; SEQUENCE ALIGNMENT; SEX FACTORS; VIRUS ACTIVATION;

EID: 84960125975     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-016-1187-z     Document Type: Article

References (34)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395–403.
2. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;9(30):2212–9.
3. Lin CL, Kao JH. Perspectives and control of hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2015;114:901–9.
4. Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med. 2004;350:1118–11129.
5. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.
6. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975;2:528–30.
7. Liu CJ, Chen PJ, Chen DS, et al. Hepatitis B virus reactivation post-cancer chemotherapy: pathogenesis and management. Hepatol Int. 2013;7:316–26.
8. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68–9.
9. Umemura T, Tanaka E, Kiyosawa K. Kumada H; Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52–6.
10. Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV REactivation in B-Cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61(5):719–29.
11. Rehermann B, Ferarri C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104–8.
12. Yotsuyanagi H, Yasuda K, Iino S, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology. 1998;27:1377–82.
13. Lin CL, Kao JH. HBV Genotypes and Variants. Cold Spring Harbor Perspect. 2015;5:a021436.
14. Hayashi K, Katano Y, Takeda Y, et al. Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. J Gastroenterol. 2008;43:558–64.
15. Sugauchi F, Tanaka Y, Kusumoto S, et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol. 2011;83:412–8.
16. Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.
17. Perrillo RP, Aach RD. The clinical course and chronic sequelae of hepatitis B virus infection. Semin Liver Dis. 1981;1:15–25.
18. Shinkai N, Matsuura K, Sugauchi F, et al. Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance. J Clin Microbiol. 2013;51:3484–91.
19. Huy TT, Ushijima H, Quang VX, et al. Genotype C of hepatitis B virus can be classified into at least two subgroups. J Gen Virol. 2004;85:283–92.
20. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4(4):406–25.
21. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39:783–91.
22. Avellón A, Echevarria JM. Frequency of hepatitis B virus ‘a’ determinant variants in unselected Spanish chronic carriers. J Med Virol. 2006;78:24–36.a.
23. Wang XY, Harrison TJ, He X, et al. The prevalence of mutations in the major hydrophilic region of the surface antigen of hepatitis B virus varies with subgenotype. Epidemiol Infect. 2015;143:3572–82.
24. Hayashi K, Katano Y, Takeda Y, et al. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. J Med Virol. 2007;79:366–73.
25. Kobayashi M, Ikeda K, Arase Y, et al. Change of hepatitis B virus genotypes in acute and chronic infections in Japan. J Med Virol. 2008;80:1880–4.
26. Takahashi K, Akahane Y, Hino K, Ohta Y, Mishiro S. Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. Arch Virol. 1998;143:2313–26.
27. Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2015;61:823–33.
28. Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57:141–50.
29. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26:6266–73.
30. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology. 1997;26:786–91.
31. Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology. 2010;53:20–8.
32. Elkady A, Aboulfotuh S, Ali EM, et al. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt. World J Gastroenterol. 2013;19:6214–20.
33. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med. 1991;324:1699–704.
34. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627–36.